MA42437A - Inhibiteurs il-8 pour utilisation dans le traitement de certains troubles urologiques - Google Patents

Inhibiteurs il-8 pour utilisation dans le traitement de certains troubles urologiques

Info

Publication number
MA42437A
MA42437A MA042437A MA42437A MA42437A MA 42437 A MA42437 A MA 42437A MA 042437 A MA042437 A MA 042437A MA 42437 A MA42437 A MA 42437A MA 42437 A MA42437 A MA 42437A
Authority
MA
Morocco
Prior art keywords
inhibitors
treatment
certain
urologic disorders
urologic
Prior art date
Application number
MA042437A
Other languages
English (en)
Inventor
Marcello Allegretti
Patrizia Angelico
Andrea Aramini
Gianluca Bianchini
Laura Brandolini
Maria Candida Cesta
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of MA42437A publication Critical patent/MA42437A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA042437A 2015-07-14 2016-07-12 Inhibiteurs il-8 pour utilisation dans le traitement de certains troubles urologiques MA42437A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15176726.6A EP3117835A1 (fr) 2015-07-14 2015-07-14 Inhibiteurs il-8 pour utilisation dans le traitement de certains troubles urologiques

Publications (1)

Publication Number Publication Date
MA42437A true MA42437A (fr) 2021-06-02

Family

ID=53757997

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042437A MA42437A (fr) 2015-07-14 2016-07-12 Inhibiteurs il-8 pour utilisation dans le traitement de certains troubles urologiques

Country Status (25)

Country Link
US (2) US12150933B2 (fr)
EP (2) EP3117835A1 (fr)
JP (1) JP6937738B2 (fr)
KR (1) KR102622924B1 (fr)
CN (1) CN107921105B (fr)
AU (1) AU2016292902B2 (fr)
CA (1) CA2991810C (fr)
CY (1) CY1125437T1 (fr)
DK (1) DK3322438T3 (fr)
EA (2) EA202190242A1 (fr)
ES (1) ES2894077T3 (fr)
HR (1) HRP20211574T1 (fr)
HU (1) HUE056439T2 (fr)
IL (1) IL256413B (fr)
LT (1) LT3322438T (fr)
MA (1) MA42437A (fr)
MD (1) MD3322438T2 (fr)
MX (1) MX2018000539A (fr)
PL (1) PL3322438T3 (fr)
PT (1) PT3322438T (fr)
RS (1) RS62413B1 (fr)
SI (1) SI3322438T1 (fr)
SM (1) SMT202100582T1 (fr)
WO (1) WO2017009323A1 (fr)
ZA (1) ZA201708608B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3342407A1 (fr) * 2017-01-03 2018-07-04 Dompé farmaceutici S.p.A. Inihibiteurs il-8 pour utilisation dans le traitement de certains troubles urologiques
EP3409277A1 (fr) 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Inhibiteurs il-8 destinés à être utilisés dans le traitement et/ou la prévention d'infections secondaires bactériennes
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11503110A (ja) * 1995-02-17 1999-03-23 スミスクライン・ビーチャム・コーポレイション Il−8受容体拮抗剤
WO2005068460A1 (fr) 2003-12-22 2005-07-28 Schering Corporation Dioxydes d'isothiazole en tant que ligands du recepteur de la chimiokine cxc et cc
HRP20090681T1 (hr) 2004-03-23 2010-02-28 Dompe' S.P.A. Derivati 2-fenilpropionske kiseline i farmaceutski pripravci koji ih sadrže
EP2166006A1 (fr) 2008-09-18 2010-03-24 Dompe' S.P.A. Acides 2-aryl-propioniques et dérivés et compositions pharmaceutiques les contenant
WO2010078403A2 (fr) 2008-12-30 2010-07-08 Lipella Pharmaceuticals Inc. Méthodes et compositions pour diagnostiquer des troubles urologiques
KR101458947B1 (ko) * 2013-03-05 2014-11-12 국립암센터 인터루킨-8 앱타머 및 이의 용도

Also Published As

Publication number Publication date
US12150933B2 (en) 2024-11-26
DK3322438T3 (da) 2021-10-18
JP6937738B2 (ja) 2021-09-22
EP3322438A1 (fr) 2018-05-23
RS62413B1 (sr) 2021-10-29
HUE056439T2 (hu) 2022-02-28
ZA201708608B (en) 2019-05-29
LT3322438T (lt) 2021-10-25
CY1125437T1 (el) 2023-03-24
US20250032461A1 (en) 2025-01-30
WO2017009323A1 (fr) 2017-01-19
PL3322438T3 (pl) 2022-01-03
BR112018000676A2 (pt) 2018-09-18
SI3322438T1 (sl) 2021-11-30
CN107921105B (zh) 2022-08-02
MD3322438T2 (ro) 2022-01-31
AU2016292902A1 (en) 2018-01-18
CA2991810C (fr) 2025-05-27
EA202190242A1 (ru) 2021-11-30
SMT202100582T1 (it) 2021-11-12
CN107921105A (zh) 2018-04-17
IL256413A (en) 2018-02-28
KR20180030075A (ko) 2018-03-21
NZ739077A (en) 2023-12-22
EP3117835A1 (fr) 2017-01-18
PT3322438T (pt) 2021-10-01
US20180200231A1 (en) 2018-07-19
JP2018520184A (ja) 2018-07-26
HRP20211574T1 (hr) 2022-02-04
AU2016292902B2 (en) 2021-06-03
IL256413B (en) 2021-04-29
EP3322438B1 (fr) 2021-09-08
EA201890312A1 (ru) 2018-08-31
CA2991810A1 (fr) 2017-01-19
MX2018000539A (es) 2018-09-06
KR102622924B1 (ko) 2024-01-09
ES2894077T3 (es) 2022-02-11

Similar Documents

Publication Publication Date Title
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3288592A4 (fr) Utilisation de cannabidiol pour le traitement de spasmes infantiles
EP3328376A4 (fr) Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA42999A (fr) Polythérapie pour le traitement de malignités
MA39753A (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
EP3835266C0 (fr) Système de traitement de liquide
EP3331527A4 (fr) Procédés de traitement de troubles du développement à l'aide de pipradrol
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3512506A4 (fr) Utilisation de la pridopidine pour le traitement du syndrome de rett
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3848022C0 (fr) Agent thérapeutique pour utilisation dans le traitement d'infections
EP2825173A4 (fr) Inhibiteurs de calmoduline pour le traitement de troubles ribosomiques et de ribosomapathies
FR3035799B1 (fr) Support pour la purification de liquides biologiques
EP3386967A4 (fr) Combinaisons pour le traitement de calculs rénaux
EP4223359C0 (fr) Dispositif non invasif de traitement du reflux gastro- sophagien pathologique
EP3397063A4 (fr) Utilisation de microbulles et de nanobulles dans le traitement de liquide
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple